XML 31 R18.htm IDEA: XBRL DOCUMENT
v3.26.1

GOODWILL AND INTANGIBLE ASSETS | 3 Months Ended
--- | ---
Jun. 27, 2026
Intangible Asset, Goodwill and Other [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | 11. GOODWILL AND INTANGIBLE ASSETS On June 5, 2026, the Company implemented an organizational realignment designed to align its commercial operations into two global reportable segments by combining the previously reported Plasma and Blood Center reportable segments into Apheresis and renaming the Hospital reportable segment to MedSurg. This organizational structure reflects how the Company is organized to manage operations, allocate resources and evaluate performance. The Company has recast goodwill assigned to the Apheresis segment as of the beginning of the year by combining the goodwill from the previous Blood Center and Plasma segments into the new Apheresis segment. Each of the Company’s reporting units were tested for goodwill impairment prior to and subsequent to the re-alignments and no impairment was identified. The changes in the carrying amount of goodwill by operating segment for the first quarter of fiscal 2027 are as follows:
| Apheresis |  | MedSurg |  | Total
| (Dollars in Thousands)
Carrying amount as of March 28, 2026 | $ | 55,931 |  |  | $ | 600,437 |  |  | $ | 656,368 |
Purchase accounting adjustments | — |  |  | 1,714 |  |  | 1,714 |
Currency translation | (22) |  |  | (1,176) |  |  | (1,198) |
Carrying amount as of June 27, 2026 | $ | 55,909 |  |  | $ | 600,975 |  |  | $ | 656,884 |
The gross carrying amount of intangible assets and the related accumulated amortization as of June 27, 2026 and March 28, 2026 are as follows:
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Weighted Average Remaining Life (Years)
June 27, 2026 | (Dollars in Thousands) |  |
Amortizable: |  |  |  |  |  |  |
Developed technology | $ | 554,029 |  |  | $ | 201,421 |  |  | $ | 352,608 |  |  | 11.4
Customer contracts and related relationships | 129,601 |  |  | 77,475 |  |  | 52,126 |  |  | 11.1
Capitalized software | 97,636 |  |  | 83,741 |  |  | 13,895 |  |  | 3.1
Patents and other | 7,422 |  |  | 4,763 |  |  | 2,659 |  |  | 5.3
Trade names | 14,608 |  |  | 7,428 |  |  | 7,180 |  |  | 10.2
Total | $ | 803,296 |  |  | $ | 374,828 |  |  | $ | 428,468 |  |  |
Non-amortizable: |  |  |  |  |  |  |
In-process software development | $ | 6,044 |  |  |  |  |  |  |
Total | $ | 6,044 |  |  |  |  |  |  |
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Weighted Average Remaining Life (Years)
March 28, 2026 | (Dollars in Thousands) |  |
Amortizable: |  |  |  |  |  |  |
Developed technology | $ | 556,631 |  |  | $ | 193,114 |  |  | $ | 363,517 |  |  | 11.6
Customer contracts and related relationships | 130,862 |  |  | 76,489 |  |  | 54,373 |  |  | 11.3
Capitalized software | 95,880 |  |  | 82,284 |  |  | 13,596 |  |  | 2.9
Patents and other | 7,422 |  |  | 4,613 |  |  | 2,809 |  |  | 5.5
Trade names | 14,720 |  |  | 7,263 |  |  | 7,457 |  |  | 10.4
Total | $ | 805,515 |  |  | $ | 363,763 |  |  | $ | 441,752 |  |  |
Non-amortizable: |  |  |  |  |  |  |
In-process software development | $ | 5,903 |  |  |  |  |  |  |
Total | $ | 5,903 |  |  |  |  |  |  |
During fiscal 2026, the Company recorded total intangible asset impairment charges of $86.5 million. This included a $9.3 million intangible impairment charge related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the MedSurg reportable segment, which was primarily recorded in the second quarter of fiscal 2026, and an intangible asset impairment charge of $77.2 million related to long-lived intangible assets associated with the acquisition of Attune Medical within the MedSurg reportable segment in the fourth quarter of fiscal 2026. In the fourth quarter of fiscal 2026, the Company acquired Vivasure and recorded $117.1 million of developed technology based on the purchase accounting valuation. Refer to Note 3, Acquisitions and Strategic Investments, for additional information regarding the acquisition. Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationship s and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years. During the three months ended June 27, 2026 and June 28, 2025, amortization expense was $11.8 million and $13.3 million, respectively. Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
|  | Amortization Expense
|  | (Dollars in Thousands)
Remainder of Fiscal 2027 |  | $ | 34,659 |
Fiscal 2028 |  | $ | 44,832 |
Fiscal 2029 |  | $ | 43,585 |
Fiscal 2030 |  | $ | 42,317 |
Fiscal 2031 |  | $ | 40,690 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible asset and goodwill. Includes, but is not limited to, finite- and indefinite-lived intangible assets, capitalized cost for internal-use software and software to be sold, leased, or marketed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration